Charles River Laboratories International, Inc. (FRA:RV6)

Germany flag Germany · Delayed Price · Currency is EUR
143.30
+0.75 (0.53%)
At close: Mar 27, 2026
Market Cap6.80B -13.5%
Revenue (ttm)3.41B -0.9%
Net Income-122.69M
EPS-2.48
Shares Outn/a
PE Ration/a
Forward PE14.34
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume0
Open143.30
Previous Close142.55
Day's Range143.30 - 143.30
52-Week Range87.70 - 193.70
Betan/a
RSI50.56
Earnings DateMay 6, 2026

About FRA:RV6

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins... [Read more]

Industry Commercial Physical and Biological Research
Founded 1947
Employees 19,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RV6

Financial Performance

Financial numbers in USD Financial Statements

News

Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

18 days ago - Seeking Alpha

Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

25 days ago - Seeking Alpha

Charles River Laboratories to Present at TD Cowen and Barclays Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at TD Cowen and Barclays Conferences.

27 days ago - Business Wire

Charles River raises annual profit view as it sells underperforming assets

Contract drug developer Charles River Laboratories raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA and private equity firm GI Pa...

4 weeks ago - Reuters

Charles River Laboratories Provides Update on Planned Divestitures

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Update on Planned Divestitures.

4 weeks ago - Business Wire

Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript

Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript

5 weeks ago - Seeking Alpha

Charles River Laboratories Q4 Review: Approaching A Bottom

Charles River Laboratories Q4 Review: Approaching A Bottom

5 weeks ago - Seeking Alpha

Charles River forecasts upbeat 2026 profit on improved demand for drug development services

Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and development services ...

5 weeks ago - Reuters

Charles River Laboratories Announces Executive Appointments

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Executive Appointments.

5 weeks ago - Business Wire

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance.

5 weeks ago - Business Wire

Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right...

6 weeks ago - GlobeNewsWire

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call.

2 months ago - Business Wire

Charles River Enters Manufacturing Collaboration with Gazi University

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Gazi University Faculty of Medicine, today announced a gene therapy contract developme...

2 months ago - Business Wire

Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL

NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

2 months ago - PRNewsWire

Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2 months ago - Seeking Alpha

Charles River to buy Cambodia-based monkey supplier for $510 million

Charles River Laboratories said on Monday it would buy one of its major suppliers of non-human primates for about $510 million as the contract research firm seeks greater control over procurement of t...

2 months ago - Reuters

Charles River Laboratories Provides Business Updates

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Business Updates.

2 months ago - Business Wire

Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan.

2 months ago - Business Wire

Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Laun...

3 months ago - Business Wire

T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform

BOSTON--(BUSINESS WIRE)--Charles River Development, a State Street Company, announced today the expansion of its relationship with T. Rowe Price through the migration to the SaaS-deployed Charles Rive...

4 months ago - Business Wire

Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript

Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript

4 months ago - Seeking Alpha

HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...

4 months ago - PRNewsWire

Charles River Laboratories to Present at Evercore Healthcare Conference

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Evercore Healthcare Conference.

4 months ago - Business Wire

Madison Small Cap Fund Q3 2025 Portfolio Activity

The small cap team initiated a new investment position in Hexcel Corporation. Hexcel is a global leader in advanced composite materials. We initiated a position in Charles River Labs in Q3. CRL is a h...

4 months ago - Seeking Alpha

Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Charles River Laboratories International, Inc. ( CRL) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Birgit Girshick - Corporate Executive VP & COO Con...

4 months ago - Seeking Alpha